Literature DB >> 33460563

Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway.

Masataka Fujikawa1, Yu-Ichiro Koma2, Masayoshi Hosono3, Naoki Urakawa3, Kohei Tanigawa1, Masaki Shimizu1, Takayuki Kodama4, Hiroki Sakamoto1, Mari Nishio4, Manabu Shigeoka4, Yoshihiro Kakeji3, Hiroshi Yokozaki4.   

Abstract

Tumor-associated macrophages (TAMs) promote tumor progression. The number of infiltrating TAMs is associated with poor prognosis in esophageal squamous cell carcinoma (ESCC) patients; however, the mechanism underlying this phenomenon is unclear. cDNA microarray analysis indicates that the expression of chemokine (C-C motif) ligand 1 (CCL1) is up-regulated in peripheral blood monocyte-derived macrophages stimulated using conditioned media from ESCC cells (TAM-like macrophages). Here, we evaluated the role of CCL1 in ESCC progression. CCL1 was overexpressed in TAM-like macrophages, and CCR8, a CCL1 receptor, was expressed on ESCC cell surface. TAM-like macrophages significantly enhanced the motility of ESCC cells, and neutralizing antibodies against CCL1 or CCR8 suppressed this increased motility. Recombinant human CCL1 promoted ESCC cell motility via the Akt/proline-rich Akt substrate of 40 kDa/mammalian target of rapamycin pathway. Phosphatidylinositol 3-kinase or Akt inhibitors, CCR8 silencing, and neutralizing antibody against CCR8 could significantly suppress these effects. The overexpression of CCL1 in stromal cells or CCR8 in ESCC cells was significantly associated with poor overall survival (P = 0.002 or P = 0.009, respectively) and disease-free survival (P = 0.009 or P = 0.047, respectively) in patients with ESCC. These results indicate that the interaction between stromal CCL1 and CCR8 on cancer cells promotes ESCC progression via the Akt/proline-rich Akt substrate of 40 kDa/mammalian target of rapamycin pathway, thereby providing novel therapeutic targets.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33460563     DOI: 10.1016/j.ajpath.2021.01.004

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  3 in total

1.  CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.

Authors:  Yujiro Kidani; Wataru Nogami; Yoshiaki Yasumizu; Atsunari Kawashima; Atsushi Tanaka; Yudai Sonoda; Yumi Tona; Kunitaka Nashiki; Reimi Matsumoto; Masaki Hagiwara; Motonao Osaki; Keiji Dohi; Takayuki Kanazawa; Azumi Ueyama; Mai Yoshikawa; Tetsuya Yoshida; Mitsunobu Matsumoto; Kanji Hojo; Satomi Shinonome; Hiroshi Yoshida; Michinari Hirata; Miya Haruna; Yamami Nakamura; Daisuke Motooka; Daisuke Okuzaki; Yasuko Sugiyama; Makoto Kinoshita; Tatsusada Okuno; Taigo Kato; Koji Hatano; Motohide Uemura; Ryoichi Imamura; Kazunori Yokoi; Atsushi Tanemura; Yasushi Shintani; Tadashi Kimura; Norio Nonomura; Hisashi Wada; Masaki Mori; Yuichiro Doki; Naganari Ohkura; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-15       Impact factor: 12.779

Review 2.  Chemokine Receptor-Targeted Therapies: Special Case for CCR8.

Authors:  Bernhard Moser
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

3.  Close Association of Intraepithelial Accumulation of M2-Skewed Macrophages with Neoplastic Epithelia of the Esophagus.

Authors:  Yumi Ichihara; Hiroshi Yokozaki
Journal:  Kobe J Med Sci       Date:  2021-06-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.